8-K: Cognition Therapeutics Advances DLB Psychosis Program

Cognition Therapeutics reports year-end 2025 financial results and provides a positive clinical development update, focusing on advancing zervimesine for dementia with Lewy bodies (DLB) psychosis.

Summary

• Cognition Therapeutics reported a net loss of $23.5 million for the year ended December 31, 2025, an improvement from a $34.0 million net loss in 2024.
• Research and development expenses decreased to $37.2 million in 2025 from $41.7 million in 2024, primarily due to the completion of SHINE and SHIMMER clinical trials.
• General and administrative expenses decreased to $10.6 million in 2025 from $12.3 million in 2024, mainly due to reduced stock-based compensation.
• Cash, cash equivalents, and restricted cash equivalents stood at $37.0 million as of December 31, 2025, with an additional $35.7 million in obligated grant funds remaining from the National Institute of Aging.
• The company estimates it has sufficient cash to fund operations and capital expenditures through the second quarter of 2027.
• Zervimesine (CT1812) is being advanced for the treatment of psychosis associated with dementia with Lewy bodies (DLB), a patient population with no approved treatment options.
• Phase 2 SHIMMER study results in DLB showed strong therapeutic responses, particularly in psychosis (102% slowing vs. placebo on NPI-4) and caregiver distress (114% slowing vs. placebo).
• A meeting with the FDA Division of Psychiatry is planned for mid-2026 to seek alignment on the registrational plan for zervimesine in DLB psychosis.
• Enrollment for the 545-patient Phase 2 START study in mild cognitive impairment (MCI) and early Alzheimer's disease was completed in December 2025, with topline results expected in 2027.
• The company aligned with the FDA on a development plan for zervimesine in Alzheimer's disease, including enrichment with p-tau217 at screening.
• Dr. David Weinstein was appointed as VP of clinical development.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive update, driven by significant clinical progress in an unmet medical need (DLB psychosis), clear regulatory pathways, and an extended cash runway, despite ongoing net losses typical for a clinical-stage biotech.

Positives

• Net loss significantly improved to $23.5 million in 2025 from $34.0 million in 2024.
• Cash, cash equivalents, and restricted cash equivalents increased to $37.0 million by year-end 2025, extending the cash runway through Q2 2027.
• The company has substantial remaining grant funds of $35.7 million from the National Institute of Aging.
• Zervimesine shows strong therapeutic responses in Phase 2 SHIMMER study for DLB psychosis, an area with no approved treatments.
• Successful completion of enrollment for the 545-patient Phase 2 START study in early Alzheimer's disease.
• Alignment with the FDA on development plans for both DLB and Alzheimer's programs provides a clear regulatory path forward.
• Zervimesine has a well-tolerated safety profile in over 450 people treated to date and robust intellectual property through 2040 with patent term extension.

Negatives

• The company continues to operate at a net loss, reporting $(23.5) million for 2025.
• Topline results for the Phase 2 START study in Alzheimer's disease are not expected until 2027, indicating a longer wait for key data in this indication.

Risks

• Competition from other therapies in development or on the market.
• Ability to secure new and retain existing grant funding.
• Challenges in growing and managing growth, maintaining supplier relationships, and retaining key employees.
• Uncertainties inherent in preliminary data, preclinical studies, and earlier-stage clinical trials being predictive of later-stage trial results.
• The timing, scope, and likelihood of regulatory filings and approvals for product candidates.
• Changes in applicable laws or regulations.
• Adverse effects from economic, business, or competitive factors, including ongoing economic uncertainty.
• Estimates of expenses and profitability may not be accurate.
• The evolution of the markets in which the company competes.
• Ability to implement strategic initiatives and continue to innovate existing products.
• Ability to defend intellectual property.
• Impacts of ongoing global and regional conflicts on business, supply chain, and labor force.
• Ability to maintain the listing of common stock on the Nasdaq Capital Market.

Future Outlook

The company's near-term focus is on advancing zervimesine for DLB psychosis, with a mid-2026 meeting planned with the FDA Division of Psychiatry to align on a registrational plan. For Alzheimer's disease, topline results from the Phase 2 START study are anticipated in 2027, which will inform the decision on a registrational program. The company expects its current cash and grant funds to support operations through the second quarter of 2027.

Management Comments

• "Our progress in 2025 and early 2026 has culminated in a clinical development plan to advance zervimesine for the treatment of psychosis associated with DLB. This patient population has no approved options today and has demonstrated their support of zervimesines advancement to registrational trials."
• "We received valuable feedback from regulators on both our DLB and Alzheimers programs."
• "With our near-term focus on DLB, our next steps are centered on a meeting with the FDA Division of Psychiatry to seek alignment on our registrational plan for zervimesine for the treatment of DLB psychosis."

Industry Context

StockSavvy.ai notes that Cognition Therapeutics is strategically targeting a significant unmet medical need in DLB psychosis, where no approved options currently exist. This could provide a substantial first-mover advantage if zervimesine progresses successfully. In the more crowded Alzheimer's market, the company's approach of allowing combination therapy with approved monoclonal antibodies (mAbs) like lecanemab and donanemab in its START study is a notable differentiator, potentially positioning zervimesine as an adjunctive therapy. The substantial grant funding from the NIH/NIA underscores the scientific merit and potential of their research in neurodegenerative diseases.

Comparison to Industry Standards

• The focus on DLB psychosis addresses a critical unmet need, as there are currently no FDA-approved treatments for this specific indication, unlike the more competitive Alzheimer's disease market which has seen recent approvals like Leqembi (lecanemab) from Eisai/Biogen and Donanemab from Eli Lilly (pending full approval).
• The company's ability to secure nearly $200 million in non-dilutive grant funding from the National Institutes of Health and related foundations is significantly above average for a clinical-stage biopharmaceutical company, demonstrating strong external validation of its scientific approach and pipeline.
• The Phase 2 SHIMMER study's reported 102% slowing of psychotic symptoms in DLB patients (NPI-4) and 114% slowing of caregiver distress (NPI Distress) represents a robust signal in a challenging patient population, potentially outperforming typical symptomatic treatments in terms of disease modification or significant symptom stabilization.
• The START study's design, allowing for combination therapy with approved mAbs like lecanemab and donanemab, positions zervimesine uniquely in the Alzheimer's landscape, potentially offering a broader treatment paradigm compared to monotherapy approaches.

Management Changes

Stakeholder Impact

• Shareholders: Potential for increased value due to positive clinical trial results, clear regulatory pathways, and extended cash runway, but also dilution from increased share count.
• Patients with DLB Psychosis: Significant positive impact as zervimesine could be the first approved treatment for this unmet medical need.
• Caregivers of DLB Patients: Potential for reduced burden and improved quality of life due to stabilization of psychotic symptoms.
• Employees: Continued employment and potential growth opportunities as clinical programs advance.
• Regulatory Authorities: Engagement with FDA and EMA indicates adherence to regulatory processes and progress towards potential approvals.

Next Steps

• Hold a meeting with the FDA Division of Psychiatry by mid-2026 to discuss the registrational plan for zervimesine in DLB psychosis.
• Finalize the registrational plan for zervimesine in DLB psychosis following the FDA meeting.
• Await topline results from the Phase 2 START study in early Alzheimer's disease, expected in 2027.
• Make a decision on the registrational program for zervimesine in Alzheimer's disease following the START study results.

Key Dates

Recommendation

The company has demonstrated significant clinical progress with zervimesine, particularly in DLB psychosis, an area with high unmet medical need and no approved treatments. Positive Phase 2 data, clear regulatory alignment with the FDA for both DLB and Alzheimer's programs, and an extended cash runway through Q2 2027 provide a strong foundation. While a clinical-stage company carries inherent risks, the strategic focus on a first-to-market opportunity and the substantial non-dilutive grant funding mitigate some of these. The improved net loss and the potential for zervimesine to address critical neurodegenerative diseases make this an attractive long-term investment for seasoned investors.

Keywords

Zervimesine, CT1812, Dementia with Lewy Bodies, DLB Psychosis, Alzheimer's Disease, Neurodegenerative Disorders, Clinical Trials, Biopharmaceutical, FDA, Phase 2, Neuropsychiatric, Cognition Therapeutics